Subscribe To
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023
– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...
October 22, 2023, 8:25 am
Revolution medicines presents promising clinical activity and safety data from phase 1/1b trial of rmc-6236
Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) — Revolution Medicine...
October 22, 2023, 6:30 am
Precede biosciences unveils groundbreaking clinical data for its pioneering liquid biopsy platform at esmo 2023 and simultaneously publishes in nature medicine
Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber Cancer Institute Results underscore the immense poten...
October 21, 2023, 8:25 am
Xencor: a mid-stage clinical company with falling losses
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...
October 20, 2023, 11:02 pm
Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tum...
October 18, 2023, 8:30 pm
3 gene editing stocks to generate super-charged gains
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroduc...
October 18, 2023, 11:05 am
Oric pharmaceuticals to present initial phase 1b clinical data for oric 114 in egfr/her2 exon 20 mutated nsclc at the european society of medical oncology (esmo) congress 2023
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and p...
October 17, 2023, 4:30 pm
Apollomics announces presentations of vebreltinib data at esmo 2023
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical co...
October 16, 2023, 10:55 pm
Merck to present latest research from oncology portfolio at esmo 2023
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research ...
October 16, 2023, 2:00 am
Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be ...
October 15, 2023, 10:05 pm
Precede biosciences announces first scientific data from its liquid biopsy platform to be presented as an oral presentation at esmo 2023
Data from more than 400 patients across 15 cancers demonstrate the significance of the Precede approach...
October 15, 2023, 10:05 pm
Olema oncology kat6 inhibitor compounds demonstrate potent anti-tumor activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SAN FRANCISCO, Oct. ...
October 12, 2023, 11:01 am
Rayzebio: initiating coverage with buy rating and a price target of $43
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re...
October 10, 2023, 2:10 pm
Why shares of tango therapeutics are dropping monday
Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various ...
October 9, 2023, 11:53 am
Plus therapeutics to participate in the jones trading healthcare summit and thinkequity conference in october
AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company ...
October 9, 2023, 11:00 am
Sutro biopharma: luvelta data for endometrial cancer treatment approaching
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial ...
October 9, 2023, 9:48 am